
Petra Anheusera Arlo Radtkeb Christian Wülfingb Jennifer Kranzd Gazanfer Belgeb Klaus-Peter Dieckmannab

Klinik für Urologie, Albertinen-Krankenhaus, and bKlinik für Urologie, Asklepios Klinik Altona, Hamburg, bKlinik für Urologie und Kinderurologie, St. Antonius Hospital, Eschweiler, Germany

Introduction

The primary diagnosis of testicular germ cell tumours (GCTs), as well as the staging of the disease, is based on 3 examination techniques: clinical examination, imaging studies and measuring serum levels of the biomarkers beta human chorionic gonadotropin, alpha-fetoprotein and lactate dehydrogenase [1]. The accurate assessment of the disease is crucial for selecting the appropriate treatment and thus forms the basis for cure. As a matter of fact, all of the 3 examination techniques listed above are hampered by methodological problems. Traditional clinical examination is the least sensitive method because it is highly dependent on personal experience. Medical imaging, for example, CT and MRI can accurately document metastases larger than 1 cm in diameter but significantly lack sensitivity in diagnosing small secondaries [2, 3]. Moreover, the specificity of medical imaging is unfavourable, too, because 10–20% false-positive results may occur [4, 5]. Serum tumour markers are expressed only by 50% of the GCT patients and certain subgroups, for example, seminoma and teratoma do not express alpha-fetoprotein [6, 7]. Lactate dehydrogenase is largely unspecific with a high number of false positive findings and is therefore recommended.
only for selected subgroups of GCT [6]. In 2011, microRNAs (miRs)371-3 and 302/367 were suggested as new serum biomarkers of GCT [8] and subsequent investigations revealed an extraordinary sensitivity and specificity of miR371a-3p, thereby rendering this marker as a very promising novel tool for diagnosing and staging testicular GCTs [9–11]. While investigating this marker systematically in a larger patient cohort, we recently experienced a number of isolated cases where the new marker miR371a-3p proved extremely helpful, clinically. We document these cases to demonstrate the exceptional usefulness of the new biomarker.

**Methods, Patients**

From January 2013 through December 2016, a total of 312 patients with scrotal abnormalities underwent serum examination within an ongoing study on the usefulness of miR371a-3p as a biomarker of testicular cancer. Of the patients, 163 had testicular GCTs, and 149 had various benign scrotal diseases with epididymitis, hydrocele and spermatocele representing the most frequent diagnoses. Information about one quarter of both, the GCT patients and those with benign diseases, has been included in previous communications [12, 13]. Results of the measurements of miR371a-3p of the other patients will be reported elsewhere. Here we separately document 5 individual patients with testicular seminoma, aged 23–43 years, who were selected for this report because of their unanticipated clinical courses. We retrospectively correlated the miR-levels with the individual clinical features and we wondered if knowledge about the marker levels would have influenced therapeutic decisions differently.

The quantitative PCR technique employed in all of the patients has been detailed earlier [14]. Serum levels of a relative quantification (RQ) value <5 were defined as normal range [13]. The laboratory technique is still in its phase of clinical evaluation. So, all of the serum samples were stored deep-frozen at −80°C until processing. Accordingly, in each of the 5 cases reported here, the results of miR measurements became available only after completion of treatment, and thus, the serum levels reported did not have any bearing on clinical decision-making.

**Results**

In all of the 5 cases, knowledge about the miR371a-3p serum levels would have significantly impacted the clinical management. Clinical details are given in following case descriptions.

1st patient: this 43-year-old man presented with left-sided testicular discomfort. Contrast-enhanced scrotal ultrasonography demonstrated unspecific irregularities of the intratesticular echo pattern (Fig. 1). Scrotal MRI was likewise inconclusive. The classical serum tumour markers were all in the normal range. Therefore, the patient was put on a surveillance schedule. As the patient...
moved to another city, he was lost to follow-up. But, enquiries disclosed that orchiectomy for classical seminoma (pT1, clinical stage [CS] 1) was performed on him at another institution 4 months after our primary assessment. The serum level of miR371a-3p at the time of primary examination was RQ = 39.45 which is much higher than the normal range. Knowledge about the elevated miR-level would clearly have changed decision-making.

No follow-up measurements of miR371a-3p were available.

2nd patient: this 36-year-old male, was enrolled as a healthy control in our previous study [13]. He had a serum level of RQ = 21.45 at the time of blood examination. Clinically, he was in a healthy condition with no signs of any testicular disease. To our surprise, he presented with a full-blown testicular seminoma (pT1, CS1) only 1 year later. At that time, the miR level had risen to RQ = 963.9 to drop to RQ = 0.01, postoperatively. Further management consisted of surveillance and after 1 year of follow-up, the patient is well and the serum level of miR371a-3p remained low at RQ = 0.0.

3rd patient: this 31-year-old patient underwent orchiectomy for testicular seminoma (pT3, CS1). Although markers were negative and no metastases were detected radiologically (Fig. 2a), the patient received adjuvant single-shot carboplatin therapy because of spermatic cord invasion of the primary and on grounds of personal choice of the patient. Twenty-six months thereafter he presented with a bulky retroperitoneal relapse (Fig. 2b). He was salvaged with 3 courses of BEP (bleomycin, etoposide and cisplatin) chemotherapy. It is to be noted here that the miR371a-3p level was at RQ = 3081.8 before orchiectomy and it continued to remain elevated at RQ = 351.8 five days after orchiectomy.

![Fig. 2. a Patient #3, left-sided testicular seminoma. Abdominal CT reveals unspecific small lymph node lateral to left iliac artery. Radiological diagnosis: no metastases detected. b Same patient, abdominal CT 26 months after adjuvant Carboplatin treatment: a chain of enlarged lymph nodes lateral to left iliac artery (arrows). Diagnosis: retroperitoneal relapse of seminoma.](image-url)
Then, no further decrease was recorded. At the time of the clinically apparent relapse, the level had risen to RQ = 4240.3 and it decreased to normal levels at the completion of salvage therapy and remained stable during the later course. This case was briefly reported previously [13].

4th patient: this 37-year-old patient had left-sided orchiectomy for a presumed occult germ cell tumour. Histologically, only germ cell neoplasia in situ (TNM: pTis) was found in the specimen. CT revealed a 1.8 cm lymphadenopathy in the para-aortal template. All of the classical serum tumour markers were negative. As histopathologically no invasive GCT was found in the left orchiectomy specimen, the lymphadenopathy was considered unspecific corresponding to a CS1. Accordingly, the patient was put on a surveillance schedule. Four months later, the lymphadenopathy had slightly increased (Fig. 3). Therefore, a laparoscopic lymphadenectomy was performed. Histologically, the specimen revealed a pure seminomatous metastasis. The patient received 3 cycles of BEP chemotherapy subsequently. Before orchiectomy, the miR371a-3p serum level was RQ = 74.4 and it was found to decrease to RQ = 20.4 three days postoperative-ly, thus clearly lying in the supra-normal range. Prior to lymphadenectomy, the level had increased to RQ = 58.5 and it dropped to RQ = 0.0 after surgical excision of the node to remain there during the later course.

5th patient: this 23-year-old man underwent orchiectomy for marker-negative testicular seminoma at another institution. CT revealed intrathoracic nodules suspicious for mediastinal lymph node metastases. Accordingly, 4 cycles of BEP chemotherapy were administered. Restaging revealed unchanged mediastinal lymphadenopathy (Fig. 4). Then, the patient was referred to our institution for further management. Thorough pulmonological examination including transbronchial biopsy disclosed sarcoidosis-like lymphadenopathy, and thus metastatic disease was excluded. In view of these results, it must retrospectively be assumed that this patient had sarcoidosis synchronously with seminoma rather than having metastatic disease. Accordingly, the serum miR371a-3p level was RQ = 0.0 at the time of re-staging after chemotherapy. Unfortunately, no miR-levels were measured at the time of first presentation. Although speculative, one would assume that miR371a-3p levels had probably been low after orchiectomy for seminoma because the mediastinal lymphadenopathy had not changed ever since. By retrospective consideration, the normal marker level would have indicated the absence of metastases at the outset and accordingly, the patient could have been
spared unwarranted chemotherapy and excessive diagnostic procedures apart from emotional distress from extended treatment.

Discussion

The central result of this report is the documentation of the exceptional usefulness of the new serum biomarker miR371a-3p in diagnosing and staging testicular GCT. In 4 of the 5 cases, the marker had indicated active germ cell cancer despite negative or inconclusive findings with the classical staging methods. In all of the 4 cases, the serum levels were clearly above the cut-off level of RQ <5 [13]. It is worthy to note that 2 cases (#1–2) represented missed primary diagnoses of testicular GCT. In the first case, unspecific clinical symptoms along with inconclusive scrotal imaging precluded the timely diagnosis of testicular GCT. Given the elevated miR-level, surgery could have been performed earlier. Strikingly, the second case had an elevated miR level more than 1 year before the clinical manifestation of the malignancy. As clinically no testicular anomalies were detectable at the time of blood examination, the elevated serum level of miR371a-3p had obviously been preceding the invasive cancer for that long time. In cases #3 and #4, small retroperitoneal metastases were missed out with the current radiological methods, while the elevated miR371a-3p levels had already pointed to the presence of metastatic disease. It thus appears that elevated miR371a-3p levels are highly sensitive and are capable of detecting GCT (primaries and secondaries) much earlier than radiological methods can.

Conversely, serum levels of miR371a-3p can also help to exclude metastatic GCT as documented in case #5, where the normal level of miR371a-p could have helped to correctly assess ambiguous radiological findings and thus exclude metastatic disease.

In conclusion, these cases clearly highlight the considerable clinical value of measuring serum levels of miR371a-3p in GCTs [15, 16].

We clearly acknowledge shortcomings of our retrospective documentation mainly lacking information regarding clinical details of the patients and particularly missing repeat measurements of miR371a-3p for comparison with the index miR-level. So, part of our conclusions is built on supposition. Notwithstanding, there is accumulating evidence that even small amounts of GCT tissue could cause serum elevation of miR371a-3p, highlighting the extraordinary sensitivity of this marker [12]. Clinically, it appears that the new marker may not only aid in revealing metastatic disease but – other than the classical markers [17] – it may also aid in assessing primary testicular masses. It is to be noted here that the marker elevation appears to precede the clinical manifestation of primary GCT by many months. Measuring serum levels of miR371a-3p apparently represents a useful tool for timely uncovering ambiguous clinical presentations of testicular cancer disease [18], and this novel biomarker clearly deserves further clinical investigation.

Acknowledgement

Dr. Raphael Ikogho helped in compiling the clinical case histories. Dirk Mumm and the Laboratory staff of Albertinen-Zentral-labor provided valuable assistance in processing and storing the serum samples.

Disclosure Statement

G. B. and K.-P.D. possess shares of miRdetect GmbH, a Bremen-based biotech company aiming to develop a commercially available laboratory test for measuring miR levels in body fluids. No other author has declared potential conflicts of interests.

Funding Sources

This study was supported by Wilhelm Sander Stiftung, Munich, and Albertinen-Stiftung, Hamburg.

References


Serum Levels of miR371a-3p

Urol Int 2017;99:98–103
DOI: 10.1159/000477446


7 Neumann A, Keller T, Jocham D, Doehn C: [Human placental alkaline phosphatase (HPLAP) is the most frequently elevated serum marker in testicular cancer]. Aktuelle Urol 2011;42:311–315.


